Type 2 Diabetes Genomics PhD: Using Long-Read Sequencing to Map Risk-Gene Regulation in Human Islets

Type 2 Diabetes Genomics PhD: Using Long-Read Sequencing to Map Risk-Gene Regulation in Human Islets

Quick Decision

The project asks how T2D risk variants alter gene regulation on each chromosome copy in human pancreatic islets. It combines Fiber-seq, Oxford Nanopore long reads and computational analysis of healthy and genetically selected T2D donor islets. A 2026 conference abstract from the same group reports a pilot in EndoC-BH1 beta cells; work in human donor islets is described as underway, with no results yet reported. The central feasibility questions are how many donors are available, how loci will be selected, what input and read depth the assay needs, and how cell composition will enter the analysis.

Exeter’s current programme and award pages list 5 January 2027; an earlier vacancy record gives 8 December 2026. Confirm the governing deadline with admissions. The Exeter award page lists Home tuition, while the national FGx initiative says Exeter awardees need not pay the UKRI-to-international-fee difference. International applicants should get the applicable arrangement in writing. The project introduction cites more than 800 million people as having T2D; that figure appears to refer to diabetes overall, so do not use it as a T2D-specific burden estimate.

Research Problem and Doctoral Work

What is unsolved and why it matters

Large T2D genome-wide association studies have found hundreds of risk loci, but an associated region does not automatically identify the causal variant, the regulated gene or the relevant cell state. A 2024 multi-ancestry analysis of 2.54 million people identified 611 loci, showing the scale of discovery and the continuing variant-to-function challenge. Many implicated signals occur in non-coding regulatory DNA. In pancreatic islets, where beta cells produce insulin, the same variant can have different effects depending on which regulatory elements are open and which other variants sit on the same chromosome copy.

Short-read assays often fragment DNA and average information across the two haplotypes. Fiber-seq is designed to keep longer stretches of sequence together while measuring chromatin accessibility and DNA methylation on individual molecules. In principle, the sequence variants and regulatory readouts on one molecule can be phased to a haplotype, helping test whether a risk allele is associated with a local accessibility or methylation difference. This resolves one layer of the problem; it does not alone prove that a variant changes gene expression, identify the target gene, or establish a causal effect on diabetes.

Advertised doctoral work

The official project PDF describes three connected tasks:

1. Generate Fiber-seq maps of regulatory activity from healthy human pancreatic islet donors.
2. Target selected diabetes-associated loci in islets from genetically selected T2D donors to investigate regulatory failure.
3. Interpret how genetic changes affect regulation and connect the results with large-scale genetic resources, including UK Biobank.

The stated approach combines experimental genetics and epigenetics with long-read sequencing and data science. Healthy and T2D islets are to be selected using genetic, clinical and existing molecular information. The project proposes Oxford Nanopore sequencing after the group’s chromatin-stencilling protocol, with additional targeted sequencing for deeper coverage at chosen loci. Computational work is expected to compare allele-specific accessibility and methylation, examine cell-type-specific regulation, annotate regulatory protein-binding sites and integrate the observations with genetic data. The project description names established Fiber-seq protocols, the group’s Oxford Nanopore platforms and high-performance computing; it also identifies human islets from Alberta IsletCore and matched genotype, RNA-seq, proteomic and single-cell transcriptomic data through a collaboration with Professor Gloyn.

Advertised outputs include detailed regulatory maps from healthy and T2D islets and annotations and datasets intended for open sharing. These are stated project aims, not guaranteed deliverables; their feasibility depends in part on sample availability, data access and the results obtained.

The public brief does not name the donor count, donor-selection thresholds, exact risk loci, target-enrichment design, read depth, replicate structure, analysis pipeline or validation assays. It also does not state whether “cell-type-specific” analysis will rely on an additional cell-resolved assay, donor metadata, computational inference or a combination. Fiber-seq gives single-fiber information, not single-cell resolution by itself. These details will determine how confidently the project can separate allelic effects from donor-to-donor variation and mixed-cell composition.

Feasibility: close pilot, important next step

The closest public precedent is a 2026 American Diabetes Association abstract by Ailsa MacCalman and Nick Owens. It used Fiber-seq in the EndoC-BH1 beta-cell model, reported 968 regions with differential chromatin accessibility between haplotypes and 575 with anti-correlated CpG methylation, and found a modest enrichment of T2D risk variants in those regions (OR 3.76; 95% CI 1.2–8.8). The abstract says the method is now being applied to healthy and disease-donor human islets. This makes the advertised direction concrete and suggests the lab has already established a relevant pilot workflow. It remains abstract-level evidence from a cell line, however; it does not yet establish assay performance, replication or biological findings in primary donor islets.

Related method studies show why the approach may help and where risk sits. Targeted Fiber-seq has measured sequence, CpG methylation and accessibility together on approximately 10-kb molecules in other loci and cell systems. A human-brain Fiber-seq study resolved cell-selective and haplotype-specific chromatin but noted that whole-genome assays practically required around one million nuclei per assay and did not provide single-cell resolution. Those numbers are not a direct estimate for this project: tissue, protocol, input and sequencing platforms differ. A separate long-read nanopore study phased regulatory elements across roughly 100-kb molecules, showing the broader potential of long reads for allelic regulation while using a different assay. The project’s stated Oxford Nanopore/Fiber-seq workflow should therefore be assessed on its own pilot data and sample requirements.

The main technical and biological questions are: how many donor islets are available in each group; how age, sex, BMI, HbA1c, medication, disease duration, ancestry and tissue quality will be handled; how target loci will be prioritized; what minimum input and coverage are needed; how technical replicates and batch effects will be controlled; and how accessibility/methylation differences will be tied to genes and phenotype. These are evidence-based questions arising from the advertised design and related literature, not claims that the project has failed to address them.

School, Programme and Field Context

The advertised host is the University of Exeter’s Department of Clinical and Biomedical Sciences. Exeter’s MPhil/PhD Clinical and Biomedical Sciences programme lists research locations at Exeter, Penryn and St Luke’s, full-time and part-time modes, and research areas including diabetes, molecular genetics, complex-disease epigenetics, RNA biology and data science. Its programme page describes capacity in long-read sequencing and single-cell omics. The project and award are listed under Exeter, and no joint or double degree is described. Confirm the final registration route, campus, registration dates and training requirements with Exeter before accepting an offer.

The setting is relevant to this project: the department’s Diabetes, Obesity and Metabolic Health theme combines genomic technologies, cell biology, data science, biostatistics and clinical/metabolic research. Exeter reports a top-10 UK position for Clinical Medicine research using combined 4-star and 3-star REF 2021 activity, as well as THE World University Rankings 2026 subject bands of top 125 for Life Sciences and top 175 for Medical and Health. These are university/department-level signals, not ratings of this studentship or guarantees of an individual supervisor’s availability.

The national MRC FGx-DLA offers up to 18 funded studentships across six core institutions—Exeter, Cambridge, Edinburgh, Imperial, King’s and Oxford. Its current guidance describes shared interdisciplinary training, cross-institutional supervisory teams, scientific meetings and networking. The national initiative lists training in functional genomics, statistics, bioinformatics, AI and machine learning, research integrity, leadership, public engagement and career development. These are programme-wide places, not 18 places on this project. The exact modules, attendance expectations and cross-site travel available to this student are not specified in the project materials.

Supervisor and Lab Assessment

Research directions and resources

The project names Nick Owens as lead supervisor. His Gene Regulatory Defects in Disease Group studies regulatory sequence variation and transcriptional control in glucose disorders, including common T2D and rare diabetes, using single-molecule footprinting and computational methods in pancreas development and adult tissue. The group describes Fiber-seq and related methods, methyltransferase labelling of accessible DNA and Oxford Nanopore readout. The project PDF further states that the group has established protocols, its own Oxford Nanopore platforms and HPC.

The project PDF names Alberta Diabetes Institute IsletCore as the human-islet source. IsletCore describes its work as isolating, biobanking and distributing human pancreatic islets and associated tissues. The project also identifies matched genotype, RNA-seq, proteomic and single-cell transcriptomic data through a collaboration with Professor Gloyn. These resources could support the project’s combination of molecular and computational analysis, but the public sources do not specify which donor datasets are already allocated, the number and phenotype of available islets, access permissions or whether all matched data will be available to the student. A live NIHR Exeter BRC project also lists Nick Owens and Ailsa MacCalman in work on human pancreatic transcriptome diversity and RNA modifications; that establishes adjacent activity, not shared data or a guaranteed role in this studentship.

The project description says the student can help shape the research direction and receive specialist supervision and training with international research collaboration. It does not define the supervision split or specify which collaborations will form part of this studentship.

Recent papers and what they establish

• MacCalman et al. (2024), “Developmentally dynamic changes in DNA methylation in the human pancreas.” The team mapped methylation across fetal pancreatic samples from 6 to 21 post-conception weeks and found developmental methylation changes at more than 21% of assessed sites, including sites annotated to monogenic-diabetes genes. This supports relevant human-pancreas and epigenetics expertise. The samples concern prenatal development, not adult T2D donor islets, and the study was not Fiber-seq.
• Wakeling et al. (2022), “Non-coding variants disrupting a tissue-specific regulatory element in HK1 cause congenital hyperinsulinism.” This Nature Genetics study linked non-coding regulatory changes to inappropriate HK1 expression in pancreatic beta cells and congenital hyperinsulinism. It is a close conceptual precedent for interpreting regulatory variants in beta cells, but it concerns rare monogenic disease rather than common T2D.
• De Franco et al. (2023), “Primate-specific ZNF808 is essential for pancreatic development in humans.” The study connected loss of ZNF808 with inappropriate activation of regulatory potential in primate-specific elements during pancreatic differentiation. It signals experience with epigenetic repression and human pancreas models, but its developmental phenotype differs from the adult-islet T2D question.
• MacCalman and Owens (2026), “Stencilling Accessible Chromatin Fibres Reveals Haplotype-Specific Regulation in Pancreatic Beta Cells.” This ADA conference abstract is the closest methods pilot: it reports haplotype-resolved accessibility and methylation in a beta-cell model and says donor-islet application is underway. As an abstract and cell-line study, it is preliminary evidence rather than confirmation of the proposed human-tissue work.

The broader literature reinforces the need for the project’s integration. A 2024 multi-ancestry T2D GWAS located 611 risk loci, while a 2023 human-islet study connected RFX6 perturbation with beta-cell chromatin architecture and T2D genetic signals. Another human-islet study found disease-associated epigenetic marks, but such associations can reflect disease state or donor factors. Together these studies support the direction; they do not guarantee that Fiber-seq alone will identify causal genes. A useful interview point is how the team plans to triangulate phased chromatin with matched expression, protein and single-cell data, and what independent evidence would count as validation.

Research Direction and Career Relevance

T2D genetics has moved from risk-locus discovery toward identifying effector variants, genes, tissues and cell states. Islet epigenomics and perturbation studies offer routes to move from statistical association to mechanism. This project has a distinctive contribution: examine accessibility and methylation in allele-resolved long molecules in human islet donors, then target selected loci and integrate them with genetic and molecular datasets. A possible research direction is to prioritize loci where a haplotype-specific chromatin change agrees with donor-level expression or protein differences. That is a reasonable analysis question, not a promised work package; the project description does not specify a final causal-validation experiment.

Technical limitations should shape interpretation. Donor islets vary in purity, viability, cell composition and clinical characteristics; limited tissue may constrain whole-genome assays or technical replication. Fiber-seq’s single-fiber measurements can reveal local chromatin patterns, but they are not equivalent to single-cell data. Sequence, accessibility and methylation can also disagree, and an allele-specific association is not proof that the variant causes T2D. The quality of donor metadata, reference genotypes, read depth and analysis controls will matter as much as the novelty of the assay.

The training could build a cross-disciplinary profile relevant to academic functional genomics, computational biology, human genetics, genomic medicine, biotechnology and research infrastructure. The UK National Careers Service describes geneticist roles in research and clinical settings; Skills England’s bioinformatics occupational map emphasizes combining life-science knowledge with data analysis and interdisciplinary work. Its 2026 life-sciences assessment projects 66,000 additional jobs (44%) in priority occupations between 2025 and 2035, with replacement demand as well. These figures are broad sector projections and skill signals; they do not forecast openings for this specialty or a specific graduate’s employment. Potential directions include postdoctoral research, functional-genomics or bioinformatics roles in universities and institutes, genomic medicine/clinical data teams, biotech target discovery, and sequencing or data-resource platforms. NHS clinical roles may have additional training or registration requirements.

Funding, Application, and Living Cost

The official Exeter MRC FGx-DLA programme page and award reference 6025 currently give a 5 January 2027 application deadline for September/Autumn 2027 entry. The earlier captured vacancy record displayed 8 December 2026. The current official date is the strongest evidence, but the discrepancy is material; confirm with Exeter Admissions and consider submitting well before the earlier date while waiting. The programme page lists applications as open from 26 October.

The studentship provides four years of full-time study, with part-time study available. Exeter’s award page specifies UK tuition fees, a UK Research Council minimum stipend of £21,805 per year at the 2026/27 rate, updated annually, and up to £5,000 per year in additional research-training and support funding. The £5,000 is not a living allowance. The national UK Human Functional Genomics Initiative page separately states that Exeter, King’s, Cambridge and Oxford students do not need to supplement UKRI funding for international fees. Because the Exeter award page itself only says UK tuition fees, the written award should confirm how this national policy applies to the individual offer. The pages reviewed do not settle visa, Immigration Health Surcharge or relocation costs; ask for these separately rather than assuming coverage.

The minimum entry requirement is a 2:1 honours degree or equivalent in a relevant field. The accepted subjects include genetics, molecular biology, biomedical science, human biology, biochemistry, medicine, healthcare professions such as nursing or pharmacology, bioinformatics, computer science or statistics. The typical English-language threshold is IELTS 7.0 overall with no component below 6.5, or equivalent, and required evidence must be supplied by the deadline.

The application uses the Exeter online form and the FGx-DLA applicant questionnaire. Applicants may rank up to three project preferences but may submit only one application; later applications are treated as unsuccessful. Required materials include a maximum two-page CV, full transcripts, two references and English-language evidence where applicable; missing documents can prevent shortlisting. Referees must not be part of the proposed supervisory team. If only referee details are submitted initially, letters are due after shortlisting and must reach Exeter seven days before interview; referees should send letters from institutional email accounts, unless a signed letter on institutional letterhead is scanned. The applicant must arrange submission. Documents must be in English, with certified translations of academic qualifications. The questionnaire asks about motivation for the DLA, an achievement, reflection on research experience and disclosure/use of generative AI.

Exeter estimates basic living costs of £1,300–£2,000 per month for a single student in Exeter or Cornwall, based on average local spending in April 2026. £21,805 divided by 12 is about £1,817 per month: approximately £517 above the low estimate and £183 below the high estimate. This is a simple comparison, not a take-home budget; it excludes personal circumstances and initial costs such as deposits, bedding, equipment and travel, and the estimate is not specific to this project’s campus. Recheck the 2027/28 stipend and local housing costs before accepting.

Applicant Fit and Preparation

Formal requirements

The published minimum is a relevant 2:1 or equivalent in one of the listed subject areas. The DLA accepts a broad mix of laboratory, clinical and quantitative disciplines, including bioinformatics, computer science and statistics. English evidence is required where applicable. The materials do not state that applicants must already know Fiber-seq, Oxford Nanopore sequencing or T2D research.

Relevant preparation

The project’s work spans human genetics, epigenetics, long-read sequencing, donor-tissue experiments and computational analysis. Applicants can use examples from research, coursework or work experience to show relevant skills such as molecular biology, sequencing, coding, statistical analysis, data quality control or interdisciplinary communication. These are preparation suggestions based on the proposed tasks, not extra admissions criteria.

A strong questionnaire response could explain how the applicant would connect a genetic signal to a regulatory mechanism while accounting for donor and cell-composition differences. It should distinguish what a chromatin association can show from what would require expression, perturbation or other validation. The official application also asks for an honest account of any generative-AI use.

Next Actions and Questions to Verify

Before applying

1. Email Exeter Admissions at pgrapplicants@exeter.ac.uk to confirm the official 5 January 2027 deadline, including whether the earlier 8 December record is obsolete; plan materials early while awaiting a reply.
2. If applying with international fee status, ask for confirmation that no UKRI tuition supplement is required at Exeter and request the tuition treatment to appear in the award offer. Ask separately about visa, Immigration Health Surcharge and relocation costs.
3. Contact Nick Owens about donor-islet numbers and phenotype mix, selected loci, sequencing input and coverage, the current status of the human-islet pilot, and which wet-lab/computational skills are most useful.
4. Confirm the exact registration route, campus, start date, 2027/28 stipend and how the annual research-training/support fund can be used.

At interview

1. How will donor age, sex, BMI, HbA1c, medication, disease duration, ancestry and tissue quality enter selection or analysis?
2. What defines the genetically selected T2D donor group, and how are loci prioritized for targeted sequencing?
3. How will the team manage Fiber-seq input, technical replication, batch effects and read-depth requirements for scarce primary islets?
4. What independent evidence will link allele-specific chromatin changes to target genes or disease-relevant function? How will cell-type-specific conclusions be supported given Fiber-seq’s single-fiber rather than single-cell resolution?
5. What roles will Alberta IsletCore and Professor Gloyn’s matched datasets play, and what data access is already approved?
6. How are supervision responsibilities divided, and which methods, training modules and cohort activities are planned for this student?

Before accepting an offer

1. Obtain a written statement covering tuition for the applicant’s fee status, the annual stipend and indexation, the four-year funding period and any visa-related or relocation costs.
2. Confirm the start/registration dates, expected campus, formal programme, training requirements and use/eligibility of the annual support fund.
3. Ask for the project’s donor/sample feasibility plan, data-use permissions and milestones so the difference between the current cell-line pilot and the proposed human-islet analyses is clear.

Evidence and Sources

Project, Award and Training

• Official project PDF
• Exeter MRC FGx-DLA programme and project list
• Exeter award ref. 6025
• UK Human Functional Genomics Initiative postgraduate research and training
• Exeter MPhil/PhD Clinical and Biomedical Sciences
• Clinical and Biomedical Sciences research themes and REF context

Supervisor, Lab and Human Tissue

• Gene Regulatory Defects in Disease Group
• Group research methods
• Group publications
• Alberta Diabetes Institute IsletCore
• NIHR Exeter BRC human-pancreas project involving Nick Owens

Supervisor and Field Publications

• MacCalman et al. (2024), human-pancreas methylation
• MacCalman and Owens (2026), Fiber-seq beta-cell abstract
• Wakeling et al. (2022), HK1 regulatory variants
• De Franco et al. (2023), ZNF808 and pancreatic development
• Suzuki et al. (2024), multi-ancestry T2D GWAS
• RFX6 functional genomics in early T2D (Nature, 2023)
• Human-islet epigenetic alterations and T2D (Nature Communications, 2023)
• Targeted Fiber-seq method study
• Fiber-seq in human brain nuclei
• Long-range nanopore phasing of regulatory elements
• Annual Review: human and mouse T2D islet functional genomics

Disease Burden, Careers and Cost

• WHO diabetes fact sheet
• IDF Diabetes Atlas global estimates
• UK National Careers Service: Geneticist
• Skills England: Bioinformatics scientist occupational map
• Skills England 2026 life-sciences skills assessment
• University of Exeter budgeting guidance

Research Limitations

The official project PDF and Exeter MRC pages are primary evidence for advertised work, supervisor, funding, eligibility and deadline. The national initiative page supplies an explicit international tuition statement not repeated locally; the written offer should reconcile it. Current official pages give 5 January 2027, while an earlier captured record showed 8 December 2026. The 2026 Fiber-seq beta-cell result is an abstract and does not establish donor-islet results. Method papers use different tissues, input and protocols. Cost and career figures are contextual estimates, not personal predictions. The project’s “over 800 million” statement appears to refer to all diabetes rather than T2D; WHO and IDF estimates differ by date and method. Research reviewed 3 November 2026.